RegenXBio Inc. (RGNX)
NASDAQ:RGNX
Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.49
-$0.26(-3.11%)
At close: 4:00 PM EST
$9.49
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.66M
Market Cap
$345.86M
Enterprise Value$418.24M
Total Cash (Recent Filing)$150.49M
Total Debt (Recent Filing)$71.07M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Aug 05, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.60
Shares Outstanding51,697,620
10 Day Avg. Volume1,628,030
30 Day Avg. Volume1,659,211
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit-3.49K
Enterprise Value/Ebitda-1.78
Forecast
1Y Price Target
$22.33Price Target Upside135.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$234.86M
Bulls Say, Bears Say
Bulls Say
Platform Licensing & Partner Revenue ModelAAV NAV platform and licensing-focused business creates durable, non-dilutive revenue levers via upfronts, milestones and royalties. Long-term partnerships scale with partner clinical progress, aligning incentives and enabling revenue capture without sole reliance on internal commercialization.
Pivotal RGX-202 Biomarker–clinical CorrelationVery strong biomarker-function correlation (>0.9) supports using microdystrophin as a surrogate endpoint, shortening development pathways and enabling potential accelerated approval. This structural linkage reduces late-stage clinical risk and can materially speed time-to-market if regulators accept the surrogate.
Pipeline Progress With Partner MilestonesConcrete partnership milestones and lifted holds provide non-dilutive funding and de-risk near-term development. Multiple programs advancing (retina, neuromuscular) diversify future revenue sources and increase probability of at least one commercial success, supporting longer-term business resilience.
Bears Say
Weak Revenue, Heavy Cash Burn & High LeverageSustained operating losses and large negative free cash flow mean the business is not self-funding. Thin equity and elevated leverage (~2.5x) increase refinancing and dilution risk, potentially forcing asset sales, partnerships or dilutive capital raises that could constrain strategic flexibility over months to years.
Limited Mature Functional DatasetA small number of 12‑month functional readouts leaves uncertainty about reproducible clinical benefit and durability. Regulators and payers typically require larger, mature datasets for approval and reimbursement; limited data raises the chance of additional trials or post‑approval requirements, delaying commercial returns.
Safety Events & Treatment ComplexityTreatment-related SAEs and a complex immunosuppression/prophylaxis regimen increase monitoring, site burden and real-world adoption friction. These structural safety and logistic demands can limit patient access, raise commercialization costs, and complicate payer negotiations even if events are manageable in trials.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $345.86M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on May 14, 2026. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$0.383.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is 0.25.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 51,697,620 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went down -37.799%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (135.34% Upside)
$22.33 (135.34% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 329.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.74%
12-Months-Change
Fundamentals
Return on Equity
-232.50%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$22.33
▲(135.34% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.91% Insiders
17.37% Mutual Funds
20.55% Other Institutional Investors
38.01% Public Companies and
Individual Investors